Navigation Links
FDA approves GlaxoSmithKline's VOTRIENT(TM) for advanced renal cell cancer
Date:10/19/2009

nths of median PFS with VOTRIENT versus 4.2 months with placebo.

The most common adverse events occurring in greater than or equal to 20% of subjects treated with VOTRIENT included diarrhea, hypertension, hair color changes, nausea, anorexia, and vomiting. Grade 3/4 adverse events among these toxicities that differed by greater than or equal to 2% included abnormal liver function, hypertension, diarrhea, asthenia, and abdominal pain. Laboratory abnormalities occurring in >10% of patients and more commonly (greater than or equal to 5%) in the pazopanib arm included increased transaminases, hyperglycemia, leukopenia, hyperbilirubinemia, neutropenia, hypophosphatemia, thrombocytopenia, lymphocytopenia, hyponatremia, hypomagnesemia, and hypoglycemia. Drug-related deaths were observed in 1.4% of 290 patients and included hepatic failure (n=2), stroke (n=1), and perforation (n=1). Hepatic dysfunction is included as a boxed warning in the product label. Other Warnings and Precautions in the label relate to QT prolongation and torsade de pointes, hemorrhagic events, arterial thrombotic events, gastrointestinal perforation and fistula, hypertension, impaired wound healing, hypothyroidism, proteinuria, and pregnancy.

VOTRIENT has a broad clinical program across multiple tumor types, with study details available at www.clinicaltrials.gov. More than 2,000 patients have been treated to date in clinical trials. VOTRIENT is not yet approved in any country other than the U.S.

About GSK Oncology

GSK Oncology is dedicated to producing innovations in cancer that will make profound differences in the lives of patients. Through GSK's revolutionary 'bench to bedside' approach, we are transforming the way treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology sector. Our worldwide research in oncology includes collaborations with more than 160 cancer centers. GSK is closing in on cancer
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Seasonal Influenza Vaccine Fluarix for Pediatric Use
2. FDA Approves New Treatment for Advanced Form of Kidney Cancer
3. FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
4. FDA Approves Cervarix, GlaxoSmithKlines Cervical Cancer Vaccine
5. U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
6. Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material
7. FDA Approves New Indication For Mirena(R) to Treat Heavy Menstrual Bleeding in IUD Users
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
10. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
11. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ) ... to Prepare Application Dossiers for Oversea Medical device ... report to their offering. The ... market of the most growth potentiality, which is ... and producers to penetrate such market. It is ...
(Date:5/22/2015)... 22, 2015 Richmond Pharmacology ... unit with a worldwide reputation for excellence in ... publications in peer reviewed medical journals. Its officers ... regulators in discussions about rules for transparency and ... (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , Clinical research is ...
(Date:5/21/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/jx648d/north_american ... "North American Active Wound Care Market by Method ... Ulcer), by End-User (In-Patient, & Out-Paient) - Analysis ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The North American ... at a CAGR of 3.1% from 2014 to ...
Breaking Medicine Technology:China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2
... 2011 Eli Lilly and Company (NYSE: LLY ... of 2011 on Thursday, October 20, 2011.  Lilly will also ... community and media to further detail the company,s financial performance. ... 9:00 a.m. to 10:00 a.m. EDT.  Investors, media and the ...
... ROG; OTCQX: RHHBY) today announced the publication of a study ... the brain of patients with Alzheimer,s disease. The study " ... with gantenerumab " is published today in the October issue ... is the first time that clinical data has been published ...
Cached Medicine Technology:Study Shows That Roche's Investigational Drug for Alzheimer's Disease Removes Amyloid Plaques From the Brain 2Study Shows That Roche's Investigational Drug for Alzheimer's Disease Removes Amyloid Plaques From the Brain 3Study Shows That Roche's Investigational Drug for Alzheimer's Disease Removes Amyloid Plaques From the Brain 4Study Shows That Roche's Investigational Drug for Alzheimer's Disease Removes Amyloid Plaques From the Brain 5
(Date:5/22/2015)... Gateway Building Concepts is experienced with all ... company specialize in include decks, additions, kitchen remodeling, interior ... much more. , The redesigned logo is a ... company. It includes two geometrical lines that represent the ... to be used with many things associated with the ...
(Date:5/22/2015)... 22, 2015 A Phase 3 ... American Society of Clinical Oncology (ASCO)’s annual meeting ... rates for those patients who received bevacizumab in ... pemetrexed/cisplatin. Bevacizumab (Avastin® Genentech, Inc.) is an antibody ... is already routinely used to treat many other ...
(Date:5/22/2015)... Ticket Down is a reputable source for authentic ... Finals Tickets . All seating for the 2015 NHL ... listing. , For the first time in some time, ... Eastern Conference. One of the original franchises in the National ... over the years, but the excitement level for this season ...
(Date:5/22/2015)... In April 2006, Veatch Consulting opened ... years they have concentrated their focus to working with ... Because of this growth and their goals to better ... Denver, Colorado, Cleveland, Ohio, Houston, Texas and now Dallas, ... dental offices, dental start ups, orthodontic practices, pediatric dental ...
(Date:5/22/2015)... 2015 Bryce Henson, local fitness icon ... Boot Camp, recently accepted his program’s 100th client. Henson ... launch of his location evidences the powerful impact his ... Fit Body Boot Camp is the nation’s most popular ... hundreds of locations across North America, Europe and Australia. ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 3Health News:Healthy Living Brought to Anaheim— New Fitness Boot Camp Acquires 100 Clients 2
... related to trend toward less sleep, researchers suspect ... many reasons why people should get adequate sleep, researchers now ... a component of type 2 diabetes. , The study included ... night of normal sleep (about eight hours) and after a ...
... ... "super chocolate", has been found effective in aiding weight loss. Users say it helps ... ... 2010 -- A special formulation of "super chocolate" has been fast increasing popularity among ...
... is safe, improves blood sugar control , THURSDAY, May ... have been encapsulated have been successfully transplanted into humans ... cells. , What,s more, scientists report, the transplanted pig ... to high blood sugar levels in the blood, improving ...
... Spring Harbor Laboratory in the USA have developed a powerful ... The breakthrough allows them to study in fine detail the ... help doctors identify dangerous tumor cells from small samples such ... in the breast. Dr James Hicks from Cold Spring ...
... study of metastatic breast cancer shows that the number ... directly correlates with the length of their survival. Reported ... the results have the potential to improve the delivery ... cells --cancer cells found in a patient,s bloodstream-- are ...
... to 10 million women take hormone therapies, which are ... hormones lost from inactive ovaries. Progestin is a hormone ... of estrogen therapy on the uterus. In studies sponsored ... found that estrogen and progestin in hormone therapies increase ...
Cached Medicine News:Health News:One Sleepless Night Ups Insulin Resistance 2Health News:Super Fat-Melting Chocolate Recipe Revealed 2Health News:Super Fat-Melting Chocolate Recipe Revealed 3Health News:Pig Pancreas Cells Help Type 1 Diabetics 2Health News:Pig Pancreas Cells Help Type 1 Diabetics 3Health News:Genome breakthrough allows scientists to identify and profile tumor cells from very small samples 2Health News:Survival in metastatic breast cancer directly linked to circulating tumor cells 2Health News:Breast cancer metastasis increases after estrogen and progestin hormone therapies, MU study finds 2
... your practice with a practice management system. ... or on paper. Your patient statements can also ... has a combined traditional software and billing services ... any computer from anywhere - multiples offices or ...
... 3 mirrors angled at 76°, 66° and 60°. ... as well as central and peripheral fundus viewing ... accurately angled and spaced 120° apart to eliminate ... portion of the lens also provides direct observation ...
... Volk 3 mirror lenses featuring ultra-clear Volk ... at 76°, 66° and 60°. The ... as well central and peripheral fundus viewing ... accurately angled to eliminate gaps in the ...
... is a direct image lens ... air-filled eye. In addition to ... air-fluid exchange vitrectomy lens, the ... make it well suited for ...
Medicine Products: